Announcements Trials
Browse Landscape

Status

Completed 108Recruiting 40Terminated 24Unknown 21Active not recruiting 21Withdrawn 7Not yet recruiting 2Enrolling by invitation 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Sarcoma 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Prostatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Melanoma 2Glioblastoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Primary Myelofibrosis 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Chordoma 1Chondrosarcoma 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × Urinary Bladder Neoplasms × Gynecologic × Clear all
NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡